Alignment Healthcare, Inc. (ALHC)
NASDAQ: ALHC · Real-Time Price · USD
16.52
-0.25 (-1.49%)
At close: Nov 14, 2025, 4:00 PM EST
16.33
-0.19 (-1.15%)
After-hours: Nov 14, 2025, 7:53 PM EST
Alignment Healthcare Stock Forecast
Stock Price Forecast
The 10 analysts that cover Alignment Healthcare stock have a consensus rating of "Buy" and an average price target of $19.75, which forecasts a 19.55% increase in the stock price over the next year. The lowest target is $17 and the highest is $23.
Price Target: $19.75 (+19.55%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Alignment Healthcare stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 3 |
| Buy | 4 | 4 | 5 | 5 | 4 | 4 |
| Hold | 3 | 4 | 3 | 3 | 3 | 3 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Hold Maintains $17 → $18 | Hold | Maintains | $17 → $18 | +8.96% | Nov 5, 2025 |
| Barclays | Barclays | Hold Maintains $13 → $18 | Hold | Maintains | $13 → $18 | +8.96% | Nov 3, 2025 |
| UBS | UBS | Hold Maintains $17 → $18 | Hold | Maintains | $17 → $18 | +8.96% | Oct 31, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $21 | Strong Buy | Initiates | $21 | +27.12% | Oct 14, 2025 |
| Keybanc | Keybanc | Hold → Buy Upgrades $21 | Hold → Buy | Upgrades | $21 | +27.12% | Aug 25, 2025 |
Financial Forecast
Revenue This Year
4.01B
from 2.70B
Increased by 48.14%
Revenue Next Year
5.18B
from 4.01B
Increased by 29.21%
EPS This Year
-0.13
from -0.67
EPS Next Year
0.07
from -0.13
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.1B | 5.7B | |||
| Avg | 4.0B | 5.2B | |||
| Low | 3.8B | 4.8B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 53.2% | 43.5% | |||
| Avg | 48.1% | 29.2% | |||
| Low | 41.0% | 18.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -0.09 | 0.35 | ||
| Avg | -0.13 | 0.07 | ||
| Low | -0.17 | -0.16 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.